(509) 228-1000 WA
(208) 754-3100 ID

Coronavirus (COVID-19) Update: Get the latest information on how we’re responding to the novel coronavirus (COVID-19). CLICK HERE »

O. Kenneth Macdonald, MD

Share

back to doctor information

Specialty

Radiation Oncology

Tumor Treating Fields (Optune)

Location:

NORTH SPOKANE

Dr. Macdonald’s career is marked by developing and honing his skills to effectively provide radiotherapy for a variety of cancer types for both females and males. 
 
Dr. Macdonald’s long-time interest in stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT) and advanced radiotherapy techniques have inspired him to seek for ways to expand the role of radiotherapy in treating a variety of primary and recurrent malignancies. His participation in research groups, clinical trials, and multi-disciplinary care teams allows opportunity for patients to undergo additional courses of radiation, once thought impractical, to achieve control, relief and confidence, in addition to the standard radiotherapy options. 
 
In his spare time, Dr. Macdonald enjoys exploring the world with his wife, spending time with his 5 children, participating in a variety of fitness activities, barbecuing, and cheering for his favorite sports teams.

Clinical Trials

TRIAL NUMBER - NCT04510129

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

TRIAL NUMBER - NCT04698915

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

TRIAL NUMBER - NCT04476797

GRECO-1: Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) with or without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC).